ECLIPSE study overview
Efficacy of cryoablation on metastatic lung tumours with a 5-year follow-up
Multicentre study showing that cryoablation offers long-term local disease control and favourable survival rates in patients with metastatic pulmonary tumours.
Thierry De Baère, MD; David Woodrum, MD, PhD; Lambros Tselikas, MD; Fereidoun Abtin, MD; Peter Littrup, MD; Frederic Deschamps, MD; Robert Suh, MD; Hussein D. Aoun, MD; Mat-thew Callstrom, MD
Journal of Thoracic Oncology • August 2021
Study objective and design
- Primary objective was to assess 5-year local control of CA in lung tumours of 3.5 cm or less in patients with pulmonary metastatic disease
- Secondary objectives to evaluate cancer-specific and overall survival, as well as evaluate changes in quality of life (QoL) over a five-year period
Study design
- Multicentre, prospective, single arm study. Patients with 60 lung metastases were treated during 48 cryoablation procedures
- Inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a max diametre of 3.5 cm
- Patients were 62.6 ± 13.3 years old (26–83)
- The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%)
- 4 sites (3 US and 1 FR)
Method
- Cryoablation was performed under general anaesthesia (67%) or conscious sedation (33%)
- Mean size of metastases was 1.4 ± 0.7 cm (0.3–3.4), and metastases were bilateral in 20% of patients
- Technical success for each treated tumour was defined as a zone of ground glass opacity, or visible ice encompassing the targeted tumour with at least a 5 mm circumferential ablative margin on CT at end of the cryoablation
- Cryoablation was performed applying a three-cycle freeze–thaw phase protocol
Results
Local tumour control rates
Freedom from local progression
Patients free from local progression without additional locoregional treatment at the index lesion
Freedom from local progression
ECLIPSE study conclusions
Cryoablation is an effective means of local tumour control in patients with metastatic lung disease, with the majority of surviving patients maintaining local tumour control at the index tumour site over 5 years. Furthermore, cancer-specific survival and overall survival were greater after 5 years than for many other local treatment modalities, including surgical resection.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.